Compare RGTI & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGTI | GKOS |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | 164 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.0B |
| IPO Year | N/A | 2015 |
| Metric | RGTI | GKOS |
|---|---|---|
| Price | $18.21 | $143.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $30.78 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 44.3M | 1.0M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $225.06 | $23.32 |
| Revenue Next Year | $99.56 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $11.14 | $73.16 |
| 52 Week High | $58.15 | $148.11 |
| Indicator | RGTI | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 67.61 |
| Support Level | $15.18 | $130.04 |
| Resistance Level | $20.04 | $147.43 |
| Average True Range (ATR) | 1.99 | 5.17 |
| MACD | -0.53 | 2.32 |
| Stochastic Oscillator | 7.09 | 93.16 |
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.